/ /

Fred Gebhart
MIGS driving the device market
Micro-invasive glaucoma surgery (MIGS) devices for glaucoma were big news in 2013. In 2014, MIGS devices represent big dollars. Steven Vold, MD, moderated the panel on the “New Horizons in Glaucoma Devices” at the 2014 Glaucoma 360 meeting.
Beyond IOP in glaucoma treatment
Intraocular pressure (IOP) is only the starting point for glaucoma treatment. Successful treatment begins with establishing an IOP goal, but there are multiple considerations that affect treatment choices. Robert Stamper, MD, explored the considerations that go into drug selection. None of the factors that should influence drug selection are new, he said, but it is easy to forget that the patient with glaucoma likely has other medical problems and is taking other medications.
Biomarker research centers on early glaucoma diagnosis
The search for glaucoma biomarkers is in high gear. Funded by Catalyst for a Cure, the research program has already produced new biomarker candidates and novel techniques that promise to advance research in glaucoma. Research is focusing on ways to diagnose glaucoma early and detect the specific, minute changes that could allow researchers to reduce vision loss.
Innovation in glaucoma thriving
Big Pharma is on the hunt for new glaucoma drugs. The pace of therapeutic development is picking up. The “New Horizons in Glaucoma Pharmaceuticals” highlighted four companies with strong new drug candidates.
Lifitegrast promising for patients using artificial tears
John Sheppard, MD, highlights results of a phase III randomized, double-masked, placebo-controlled trial of lifitegrast in dry eye patients previously on artificial tears. He presented these results, a subset analysis of the OPUS-1 phase III trial, at the 2013 meeting of the American Society of Cataract and Refractive Surgery.
Senior pharmacists: Too busy to retire
Who sez older pharmacists should be put out to pasture? Not these guys — they're too busy working to consider the possibility.
ED visits likely to increase under ACA
Massachusetts and Oregon studies show emergency department increases once patients have health insurance coverage
Pharmacy benefits move to narrower networks
While the big chains compete aggressively for preferred provider status, indies and small chains have a tougher time cutting copays and network prices.
Pharmacies rely on preferred status
Narrow pharmacy networks are booming
Longitudinal versus torsional phaco
Several new refractive surgical platforms have been introduced recently, and many ophthalmologists are discovering they find the new technologies to be more efficient and produce better results.

Poll

View Results